论文部分内容阅读
选择糖尿病肾病患者40例,随机分为治疗组20例,对照组20例。治疗组静脉点滴前列地尔(凯时)10微克加入0.9%氯化钠100毫升,每日一次,硫辛酸0.6克加入0.9%氯化钠250毫升,每日一次,连续3周;对照组静脉点滴前列地尔(凯时)10微克加入0.9%氯化钠100毫升,每日一次,但控制血压、血脂、血糖等其他治疗方法两组相似。观察两组患者治疗前后尿微量白蛋白的变化。结果:经前列地尔联合硫辛酸治疗后,患者尿微量白蛋白明显下降,与治疗前相比有显著性差异(P<0.05)。结论:前列地尔联合硫辛酸是早期糖尿病肾病安全、有效的治疗方法,早期应用有利于延缓早期糖尿病肾病的进展。
Forty patients with diabetic nephropathy were randomly divided into treatment group (20 cases) and control group (20 cases). Treatment group intravenous alprostadil (Kai) 10 micrograms of 0.9% sodium chloride added to 100 ml once daily, lipoic acid 0.6 g 0.9% sodium chloride 250 ml, once a day for 3 weeks; the control group of veins Dripping alprostadil (Kay hours) 10 micrograms added 0.9% sodium chloride 100 ml once daily, but the control of blood pressure, blood lipids, blood sugar and other treatment methods similar to the two groups. The changes of urinary albumin before and after treatment in both groups were observed. Results: Urine microalbumin decreased significantly after treatment with alprostadil combined with lipoic acid, which was significantly different from that before treatment (P <0.05). Conclusion: Alprostadil combined with lipoic acid is a safe and effective treatment for early diabetic nephropathy, and early application is beneficial to delay the progression of early diabetic nephropathy.